ALB and diffuse large B-cell lymphoma: Besides the classical IPI scoring system, several researchers analyzed the medical records of DLBCL patients and investigated whether routinely documented parameters (demographic data, clinical stage, ECOG (Eastern Cooperative Oncology Group), GCB subtype, Hans algorithm, CBC (Complete Blood Count) indices, and serum markers such as albumin and cholesterol) could serve as independent predictors [13].